Focus: Third Pole Therapeutics is a biotechnology company focused on inhaled nitric oxide delivery systems for respiratory indications, particularly pulmonary hypertension. The company operates as a pre-revenue biotech with a highly specialized therapeutic focus.
Profile data last refreshed 4h ago · AI intelligence enriched 3w ago
Career fit depends on risk tolerance for early-stage science; limited hiring activity signals company is either heavily constrained financially or in dormant development phase.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Third Pole Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Third Pole Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Recent peer-reviewed publications with author affiliations at this company
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo